Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Pelemans

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
AIDS Research and Human Retroviruses|March 10, 1998
A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781J Balzarini, H Pelemans, R Esnouf, et al.
Molecular Pharmacology|April 25, 2000
Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitorsH Pelemans, R Esnouf, E De Clercq, et al.
Molecular Plant-Microbe Interactions : MPMI|May 1, 1995
Identification and characterization of a Rhizobium leguminosarum bv. phaseoli gene that is important for nodulation competitiveness and shows structural homology to a Rhizobium fredii host-inducible geneJ Michiels, H Pelemans, K Vlassak, et al.
Archives of Microbiology|January 1, 1994
Characterization of the Rhizobium leguminosarum biovar phaseoli nifA gene, a positive regulator of nif gene expressionJ Michiels, I D'hooghe, C Verreth, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 12, 1996
Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitorsJ Balzarini, H Pelemans, A Karlsson, et al.
Science (New York, N.Y.)|January 10, 1997
Reverse transcriptase fidelity and HIV-1 variationJ Balzarini, H Pelemans, E De Clercq, et al.
The Journal of Biological Chemistry|December 16, 1998
Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptaseH Pelemans, R M Esnouf, H Jonckheere, et al.
Virology|August 16, 2001
Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RTH Pelemans, R Esnouf, K L Min, et al.
Biochemical and Biophysical Research Communications|August 14, 1996
Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109J Balzarini, O Wedgwood, J Kruining, et al.
The Journal of General Virology|June 20, 1998
A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152H Pelemans, R M Esnouf, M A Parniak, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
AIDS Research and Human Retroviruses|March 10, 1998
A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781J Balzarini, H Pelemans, R Esnouf, et al.
Molecular Pharmacology|April 25, 2000
Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitorsH Pelemans, R Esnouf, E De Clercq, et al.
Molecular Plant-Microbe Interactions : MPMI|May 1, 1995
Identification and characterization of a Rhizobium leguminosarum bv. phaseoli gene that is important for nodulation competitiveness and shows structural homology to a Rhizobium fredii host-inducible geneJ Michiels, H Pelemans, K Vlassak, et al.
Archives of Microbiology|January 1, 1994
Characterization of the Rhizobium leguminosarum biovar phaseoli nifA gene, a positive regulator of nif gene expressionJ Michiels, I D'hooghe, C Verreth, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 12, 1996
Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitorsJ Balzarini, H Pelemans, A Karlsson, et al.
Science (New York, N.Y.)|January 10, 1997
Reverse transcriptase fidelity and HIV-1 variationJ Balzarini, H Pelemans, E De Clercq, et al.
The Journal of Biological Chemistry|December 16, 1998
Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptaseH Pelemans, R M Esnouf, H Jonckheere, et al.
Virology|August 16, 2001
Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RTH Pelemans, R Esnouf, K L Min, et al.
Biochemical and Biophysical Research Communications|August 14, 1996
Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109J Balzarini, O Wedgwood, J Kruining, et al.
The Journal of General Virology|June 20, 1998
A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152H Pelemans, R M Esnouf, M A Parniak, et al.
Pageof 2